Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples